NCT06697301Phase 2, phase 3Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2035-12Estimated

Enrollment · participants740Estimated

Source updated2026-05-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Advanced Melanoma

Treatments or interventions studied

EIK1001Drug
Pembrolizumab (KEYTRUDA® )Drug

Primary outcomes · main study measures

Read the study measures

measure: Progression Free Survival (PFS); description: Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.; timeFrame: up to 5 years; measure: Overall survival (OS); description: Overall survival (OS) defined as the time from randomization to death due to any cause.; timeFrame: up to 5 years; measure: Objective Response (OR) (Dose Optimization Only); description: Objective Response (OR; defined as participants who demonstrate confirmed complete response \[CR\] or partial response \[PR\] by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 as assessed by the Investigator) (Dose Optimization Only).; timeFrame: up to 5 years; measure: Adverse Events (AEs) (Dose Optimization Only); description: Adverse events (AEs), and discontinuation of study treatment due to an AE (Dose Optimization Only). An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.; timeFrame: up to 2.5 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history